A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.
Vidimar V, Licona C, Cerón-Camacho R, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C.
Vidimar V, et al. Among authors: mellitzer g.
Cancer Lett. 2019 Jan;440-441:145-155. doi: 10.1016/j.canlet.2018.09.029. Epub 2018 Oct 17.
Cancer Lett. 2019.
PMID: 30339780